U.S. National Institute of Health www.cancer.gov National Cancer Institute
National Cancer Institute
NCI Alliance for Nanotechnology in Cancer

Skip Header Links
About Programs News Resources Events Intranet Login
National Cancer Institute


NCI Alliance for
Nanotechnology in Cancer


Nanotech News

 

  Current Month

  News Archive

Monthly Features
News Releases
Alliance News
News Conferences

Sign-up Today


 
Back

Nanotech News


September 18, 2006

Detecting Cancer with Silica Nanoparticles

Tumor necrosis factor-alpha (TNF-æ) is a widely accepted biomarker for cancer, but the minute amounts of this protein circulating in blood makes detecting the molecule and measuring its concentration accurately a technological challenge. Using silica nanoparticles labeled with the molecule guanine, researchers at the Pacific Northwest National Laboratory have now created a simple and inexpensive electrochemical method that detects TNF-æ at clinically useful levels. Moreover, this assay is amenable to miniaturization, suggesting that it could be easily incorporated into a microfluidics-based assay system.

Reporting its work in the journal Analytical Chemistry, a research team headed by Yuehe Lin, Ph.D., loaded guanine molecules onto the surface of silica nanobeads that also contained a chemical anchor known as avidin. They also attached biotin, which binds with extraordinary strength to avidin, to an antibody that binds to the TNF-æ protein. The researchers attached a second antibody, one that binds to a different part of the TNF-æ protein, to a carbon electrode, which functions as the electrochemical sensor.

When TNF-æ is present in a solution added to the antibody-labeled electrode, it binds to the antibody. Adding the second antibody produces a sandwich around the TNF-æ molecule. At this point, the researchers then added their labeled silica nanoparticle, which binds to the antibody-TNF-æ sandwich. In a final step, the investigators added a molecule that reacts with the guanines on the nanoparticle, creating an electrical current that the electrode senses. The current flowing into the electrode is proportional to the amount of TNF-æ bound to the first antibody. Experiments with this system showed that the limit of detection for the device is approximately 2 picomolar, well within the range needed to detect physiological levels of TNF-æ.

This work is detailed in a paper titled, “Sensitive immunoassay of a biomarker tumor necrosis factor-æ based on poly(guanine)-functionalized silica nanoparticle label.” This paper was published online in advance of print publication. An abstract of this paper is available at the journal’s website.
View abstract.


A Service of the National Cancer Institute
National Cancer Institute Department of Health and Human Services National Institutes of Health FirstGov.gov Nanotechnology Characterization Lab Nanotechnology Teaming Portal